<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1505715</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Community series in the role of toll-like receptors and their related signaling pathways in viral infection and inflammation, volume II</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Planz</surname>
<given-names>Oliver</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/70339"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kircheis</surname>
<given-names>Ralf</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1068532"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Immunology, Faculty for Cell Biology, University of T&#xfc;bingen</institution>, <addr-line>T&#xfc;bingen</addr-line>, <country>Germany</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Research &amp; Development, Syntacoll GmbH</institution>, <addr-line>Saal an der Donau</addr-line>, <country>Germany</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited and Reviewed by: Francesca Granucci, University of Milano-Bicocca, Italy</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Ralf Kircheis, <email xlink:href="mailto:ralf.kircheis@admedsol.com">ralf.kircheis@admedsol.com</email>; Oliver Planz, <email xlink:href="mailto:oliver.planz@uni-tuebingen.de">oliver.planz@uni-tuebingen.de</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1505715</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>10</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>10</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Planz and Kircheis</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Planz and Kircheis</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/60605/community-series-in-the-role-of-toll-like-receptors-and-their-related-signaling-pathways-in-viral-infection-and-inflammation-volume-ii/overview" ext-link-type="uri">Editorial on the Research Topic <article-title>Community series in the role of toll-like receptors and their related signaling pathways in viral infection and inflammation, volume II</article-title>
</related-article>
<kwd-group>
<kwd>toll-like receptor</kwd>
<kwd>signaling pathway</kwd>
<kwd>viral infection</kwd>
<kwd>inflammation</kwd>
<kwd>tolerance</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="2"/>
<word-count count="300"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Molecular Innate Immunity</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>The second volume of our Community Series on &#x201c;The Role of Toll-like Receptors and their Related Signaling Pathways in Viral Infection and Inflammation&#x201d; delves into the intricate mechanisms through which TLRs influence the immune response against viral pathogens. This Research Topic, led by diverse researchers, expands our understanding of TLRs and their role in inflammation.</p>
<p>Included studies comprehensively examine how TLR activation regulates different stages of inflammation. For example, research by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2018.00933">Butcher et&#xa0;al.</ext-link> highlights macrophage tolerance in TLR signaling, crucial for adapting to chronic endotoxin exposure and mitigating prolonged pro-inflammatory cytokine production. This adaptation aims to protect host tissues from damage, observed across various TLR ligands, particularly TLR4&#x2019;s ligand lipopolysaccharide (LPS), which induces global shifts towards anti-inflammatory responses.</p>
<p>Additionally, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2017.01820">Ricci-Azevedo et&#xa0;al.</ext-link> discuss lectins as TLR agonists with immunomodulatory properties. Plant lectin ArtinM and microbial lectins interact with TLR2 and TLR4, triggering NF-&#x3ba;B activation and IL-12 production <italic>in vitro</italic>. <italic>In vivo</italic> studies show these lectins confer resistance to intracellular pathogens. Lectins from pathogens like Toxoplasma gondii and Paracoccidioides brasiliensis also activate TLRs, suggesting potential for new pharmaceutical tools against infections and tumors.</p>
<p>Moreover, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2018.00072">Lu et&#xa0;al.</ext-link>&#x2019;s review underscores TLRs&#x2019; significant role in inflammatory bowel disease (IBD), a chronic global condition. Dysfunctions in TLR-mediated pathways contribute to IBD pathogenesis and influence treatment efficacy, prompting exploration of novel therapeutic strategies.</p>
<p>Lastly, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2024.1379754">Popotas et&#xa0;al.</ext-link> explore sex-specific immune responses in acute inflammatory diseases, attributing these differences to genes on the X chromosome encoding TLRs. Their review highlights distinct inflammatory patterns between sexes, crucial for tailoring clinical approaches.</p>
<p>This volume aims to advance our understanding of TLRs in inflammation, driving targeted therapy development and improving patient outcomes. We extend gratitude to all contributors for their invaluable insights and dedication to this critical field.</p>
</body>
<back>
<sec id="s1" sec-type="author-contributions">
<title>Author contributions</title>
<p>OP: Conceptualization, Writing&#xa0;&#x2013; original draft. RK: Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s2" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>Author RK was employed by company Syntacoll GmbH.</p>
<p>The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec id="s3" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</back>
</article>